<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141514</url>
  </required_header>
  <id_info>
    <org_study_id>2019/CHU/03</org_study_id>
    <nct_id>NCT04141514</nct_id>
  </id_info>
  <brief_title>Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy</brief_title>
  <acronym>CHEMO-FAST</acronym>
  <official_title>Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the effect of the practice of a short-term partial fasting
      compared to a usual alimentation on nausea and vomiting within 5 days after the start of a
      chemotherapy session on 2 successive chemotherapy courses (4 sessions of chemotherapy) in
      patients starting treatment with highly emetogenic chemotherapy (ABVD or AVD protocol).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in fasting arm will practice partial fasting during 3 days (D-1, D1 (D day of
      chemotherapy) and D2) following a food guide during 4 chemotherapy sessions. Patients in
      usual alimentation arm will continue to take food as usual practice.

      In each arm, patients will be interviewed at each chemotherapy sessions about nausea and
      vomiting (number and intensity of nausea and vomiting, treatments taken). Denutrition,
      quality of life improvement, compliance to partial fasting, treatment response will be
      evaluate too.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>Day 1 (first day of the chemotherapy cycle),</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 2 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 3 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 4 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 5 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nausea Post Chemotherapy</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual alimentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>therapeutic fasting</intervention_name>
    <description>fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient starting a treatment by chemotherapy ABVD or AVD

          -  patient affiliated to a social security scheme

          -  patient who gives his informed consent before any procedure related to the study

        Exclusion Criteria:

          -  patient with diabetes

          -  patient with recent gastric ulcer

          -  patient with low BMI (less than 18,5 for patients under 70 or less than 21 for patient
             over 70)

          -  albuminemia &lt;35

          -  patient wiht loss weight &gt; 10% in 6 months

          -  pregnant or lactating women

          -  chronic alcoholism

          -  unable to understand the objectives and risks of the study

          -  patient with psychiatric desorder, under guardianship or under judicial protection

          -  patient who cannot read
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Elora MUSSARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de La Réunion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie TECHER</last_name>
    <phone>+262 (0)262 90 62 89</phone>
    <email>emilie.techer@chu-reunion.fr</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

